Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
|Poll|February 14, 2019
Mini Quiz: Supported Housing for Vulnerable Patients
Author(s)Sonya Gabrielian, MD, MPH
What factors are associated with loss of supported housing for chronically homeless patients with serious mental illnesss? Take the quiz and learn more.
Advertisement
What factors are associated with loss of supported housing?
What factors are associated with loss of supported housing?
Advertisement
Related to this article
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Don't miss out on these CME articles! Test your knowledge here.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
3
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
4
What Makes Us Human? The Role of Psychiatry and the Future DSM
5